Lifecore Biomedical, Inc. \de\: Pay

Lifecore Biomedical, Inc. \de\ paid its 4 named executives $10.3M in total in FY2025 (May). CEO Paul Josephs was paid $1.1M of that.

Pay$100 in the stock at the end of FY23 → $83
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Ryan D. LakeExecutive Vice President, Chief Financial Officer
FY2025 (May)
1 year
Thomas D. SalusChief Legal and Administrative Officer
FY2025 (May)
1 year
Paul JosephsPresident and Chief Executive Officer
FY2025 (May)
FY2024 (May)Not disclosed
2 years
John D. MorbergFormer Executive Vice President, Chief Financial Officer
FY2025 (May)
FY2024 (May)Not disclosed
FY2023 (May)
FY2022 (May)Not disclosed
FY2021 (May)Not disclosed
5 years

CEO pay against the pay peers

In FY2025 (May), the median CEO pay of the 6 peers with pay on file was $3.7M. The CEO of Lifecore Biomedical, Inc. \de\ was paid $1.1M, 69% below the median.

  1. 1Artivion
  2. 2Regenxbio
  3. 3Cerus
  4. 4Personalis
  5. 5Aclaris Therapeutics
  6. 6Codexis
  7. 7Lifecore Biomedical, Inc. \de\
  8. 8ANI PharmaNot disclosed
  9. 9Anika TheraNot disclosed
  10. 10Avid BioservicesNot disclosed
  11. 11ChromaDexNot disclosed
  12. 12DLH HoldingsNot disclosed
  13. 13Harvard BioscienceNot disclosed
  14. 14Infu SystemNot disclosed
  15. 15InotivNot disclosed
  16. 16Natural Alternatives InternationalNot disclosed
  17. 17OraSure TechNot disclosed
  18. 18ProPhase LabsNot disclosed
  19. 19Societal CDMONot disclosed
  20. 20Standard Bio ToolsNot disclosed
  21. 21SurmodicsNot disclosed
  22. 22Sutro BiopharmaNot disclosed
  23. 23Xtant MedicalNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.